Advanced Materials (24)
Darkside Scientific
Darkside Scientific, LLC has developed the world’s first and only electroluminescent coating technology, LumiLor paint. This patent-pending product is capable of illuminating practically any surface, including metals, plastics, wood, fiberglass, and glass. The company differs from what is commercially available today as it can apply LumiLor to any shape, including complex curves and small items. The product can also apply to surfaces in a permanent manner that sill flexes with plastics and does not delaminate.
Website: http://darksidescientific.com/
DAK Scientific
DAK Scientific, Inc. is a medical device development company with a focus on designing products related to the Peripherally Inserted Central Catheter (PICC) market.
This medical device development company was founded by Deborah Kreatsoulas and Nicholas Kreatsoulas, DO in January 2017. Dr. Kreatsoulas worked as a Medical Director of Case Management in a community hospital where he managed patient flow throughout the hospital system. A problem continued to surface with admitted patients: What do you do with a IV drug user who has a PICC line? A typical PICC line patient can be discharged home to continue their therapy in an outpatient setting. However, the IV drug abuser or patient at risk for tampering with their PICC line ports cannot be and presents two problems: 1) they require constant monitoring which puts significant strain on hospital staff and 2) an unsecured PICC line port offers an easy opportunity to continue illicit drug use. The founders also discovered that there was a significant increase in infection rates, due to poor sterilization techniques by healthcare professionals at the PICC line injection ports.
The company’s goal is to provide a safe, secure, and successful experience for patients with PICC lines. PICC line insertions exceeded 2.9 million in 2015 and expect an annual growth rate of 8%. The total U.S. PICC line market was approximately $500 million in 2015.
In May 2017, DAK Scientific filed their first provisional patent defining the intellectual landscape of our product designs and is now entering a re-design phase, hoping to have a final product design with prototype modeling for product refinement in the next 6-9 months. The company is collaborating with Balance, Inc. of Cleveland, Ohio for our medical design prototype and product platforms.
Collamedix
CollaMedix is an early stage healthcare company that is developing collagen-based medical devices. Patented technology licensed from Case Western Reserve University allows a novel method of fabrication of pure-collagen threads and biofabric called CollaFabric. These materials can be used to create pure-collagen mesh or other medical devices. The beneficial product features of CollaFabric technology allow an ideal pure-collagen implant for various medical applications.
Coag Corp.
Coag Corp. has developed a single-use prescription product to control nosebleeds. The device works for people of all ages, but is primarily formulated for anticoagulated patients. The company won a $25,000 Innovation Fund grant in November 2013.
Cleveland Whiskey
Cleveland Whiskey unabashedly brings 21st century science and technology to an industry steeped in traditional practice. Making whiskey is done in pretty much the same way it’s been done for centuries and that’s okay, it works, in fact it works quite well. Indeed, it’s a $20 Billion world-wide market, a market that’s growing around the world.
Read more about Cleveland Whiskey in Forbes and The New York Times.
Website: http://www.clevelandwhiskey.com
BubbleClear
BubbleClear is a wastewater treatment company developing biomedia technology to increase the efficiency and ability for new and existing wastewater treatment technologies to treat wastewater. The company is developing and testing a new highly porous biomedia that could significantly increase the performance of any wastewater treatment system that uses biomedia.
The company received a $25,000 Innovation Fund A award in August 2015.
Website: https://www.bubbleclear.com/
Aspire
Aspire Technologies, Inc. was founded after Todd Kelley, former sports trainer and coach, saw athletes struggling with training drills. Current products on the sport performance market offer limited capabilities, resulting in athletes modifying and manipulating equipment in a cumbersome way to fit their needs. Aspire's is developing a lightweight running wearable worn by athletes and uses a mobile app to effectively increase maximum speed rates and deliver high intensity data metrics. While most products on the market tend to be similar, Aspire's mobile app stands out by offering reliable wireless signaling that allows athletes to quickly release from equipment at the push of a button rather than manually pulling Velcro straps or plastic buckles to naturally propel an athlete into maximum speed. This eliminates timing and safety issues that plague athletes by providing real-world data and the timing and precision to control training drills that maximize athletic speed potential.
ABSMaterials
Absorbent Materials Company LLC (ABSMaterials) develops reactive glass products and nanosands for remediation or site-cleanups of volatile organic and related spills, plumes or gas discharge. The company's products are engineered to be fully reversible, highly stable, hydrophobic and capable of capturing and recovering a range of hydrocarbons and pervasive solvents.
Website: www.absmaterials.com
ABEMIS
ABEMIS LLC develops novel, motorized microscopy and micro-testing systems for both standard imaging and challenging custom imaging/testing tasks. ABĒMIS was founded in 2015 by Todd Doehring, Ph.D. and William (Bill) Nelson who have developed the lead technology and financial/marketing strategies.
The goal of our company is to produce cutting-edge micro-systems that are flexible, customizable, durable/portable, and affordable (appx. 10x less expensive!) compared to existing systems. A huge market opportunity exists because current systems cost $100-200k (or much more) and are locked into proprietary software/hardware. We strive to enable improved local point-of-care and clinical laboratory health care systems – as well as non-clinical uses such as advanced field microscopy (e.g. archaeology, biology, more…).
Our main product is the ABĒMIS MezoScopeTM system with full X-Y-Z motor control, rapid imaging and gantries/software -- all developed (and customizable) in-house. Our software (.NET C#, GPU imaging, OpenCV) is a new milestone in the successful development of the new fast motor-control V.3+ system which is available now and in production for clients such as the Lerner Research Center (Cleveland Clinic Foundation). Demo systems are being built for national distributors. Next steps are development of the new V.4 ‘bullet-proof’ durable/portable system with AI guided software-assisted (deep-learning), live specimen feature-tracking, web interface for tele-medicine applications, and cloud solutions for image database storage/processing -- among other novel hardware/software innovations and features.
Website: https://www.abemis.com/
AATRU Medical Corporation
Aatru Medical is developing a wound dressing product platform that leverages market-ready technology that will disrupt the multi-billion dollar wound therapy market (NPWT). With our focus on the negative pressure wound therapy market space, Aatru is designing the Industry’s first and only fully self-contained negative pressure dressing that eliminates the need for pumps, batteries, hoses, and canisters that are found in today’s portable NPWT products.
Because of the innovative and streamlined design of the patent-pending Aatru dressing, our bandage will be easier to apply for the caregiver, offer discretion to the patient, and can substantially reduce the cost of treatment for the hospital, insurance provider, and patient.
Aatru was founded in Cleveland by a team of highly experienced entrepreneurs. The management is being supported and advised by a fully-rounded group of medical experts, wound-care specific Industry leaders, a dedicated IP legal team, and design and manufacturing innovators.
With three provisional patent filings, and demonstrable early-stage prototype dressings, Aatru is working towards FDA submission by year’s end.
In addition to the wound care market, there are substantial market opportunities for the Aatru platform, specifically in the post-surgical incision market, and tissue treatment in the cosmetic and aesthetic markets.
Website: https://aatru.com/
Follow Us
